Rituximab Trumps Natalizumab in MS Relapse

Rituximab Trumps Natalizumab in MS Relapse

Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world “comparative effectiveness study,” showed relative risk for 2 years of relapse freedom in patients treated with natalizumab…

Read More